Page 3 - Ventricular Dysfunction News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Jan 25, 2021 (margetuximab-cmkb) trastuzumab), both with chemotherapy In the U.S., MARGENZA is approved, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease ROCKVILLE, MD, Jan. 25, 2021 (GLOBE NEWSWIRE) --MacroGenics, Inc.. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publica...

Daiichi Sankyo Company, Limited: ENHERTU Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca's ENHERTU (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. This press release features multimedia. View the full release here: https://www.businesswire.com/...

New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo's Continued Commitment in Lung Cancer will be featured as late-breaker presentation Updated TROPION-PanTumor01 results of datopotamab deruxtecan in patients with advanced NSCLC to be highlighted Biomarker analysis from phase 1 trial of patritumab deruxtecan in patients with previously treated metastatic or locally advanced EGFR mutated NSCLC to be presented Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will present new research data across its DXd ADC portfolio including ENHERTU ...